The First New Kind of ADHD Drug in Years Is Waiting on the FDA's Call

In both adult trials, patients on centanafadine showed statistically significant improvement over placebo on the main symptom scale. Both the 200 mg and 400 mg doses cleared the bar. In adolescents, the high dose (328.8 mg) beat placebo convincingly, with patients improving by 18.5 points on the ADHD rating scale versus 14.15 for placebo (p=0.0006). The pattern held in children, where the high dose separated from placebo by week one and stayed ahead through week six.

The low dose told a different story. In both pediatric trials, it failed to reach statistical significance on the primary endpoint. That's not a dealbreaker for approval, but it does mean the drug's sweet spot is clearly at the higher dose.

There's also a Phase 3b trial that Otsuka completed in April 2026, targeting adults with both ADHD and anxiety (a combo that's extremely common). Centanafadine beat placebo on ADHD symptoms and on the Hamilton Anxiety Rating Scale, posting a statistically significant 1.92-point advantage on anxiety (p=0.02). It's a modest effect, but for a drug primarily designed for attention problems, showing legitimate anxiety relief is a compelling bonus.

The Safety Profile Looks Manageable

No drug is side-effect-free, and centanafadine is no exception. The most common complaints across trials were decreased appetite, nausea, headache, and rash in kids, and insomnia, nausea, decreased appetite, and dry mouth in adults. Side effects were generally mild to moderate.

In a year-long adult safety study, 61.4% of participants reported at least one adverse event, but serious events were rare: just 12 out of roughly 660 patients, and none were considered related to the drug. No deaths occurred in the program.

Critically, Otsuka emphasizes centanafadine's low potential for abuse and dependence. That's a big deal. Stimulants work well, but they're controlled substances with real diversion risks (college campuses, anyone?). A non-stimulant that approaches stimulant-level efficacy without the DEA paperwork would be a genuine clinical advance.

A Growing Market Is Watching

The U.S. accounts for a large share of the global ADHD drug market. But here's the interesting subplot: non-stimulants are the fastest-growing segment, expanding at 7 to 9% annually.

That non-stimulant segment is anchored by cheap generic atomoxetine on one end and branded Qelbree (from Supernus Pharmaceuticals) on the other. Centanafadine would create a third major branded pole in this space, backed by Otsuka's considerable CNS sales infrastructure (the company already markets treatments for depression and psychosis).

Wall Street's likely read? Centanafadine is a solid filing with a favorable, though not certain, shot at approval. Priority review plus multiple positive trials typically puts a drug in the 60 to 75% approval probability range, with the main uncertainty coming from its first-in-class mechanism and the FDA's traditionally cautious stance on drugs prescribed to millions of children. An advisory committee meeting wouldn't be surprising; first-in-class CNS drugs in big pediatric markets often get one.

Commercially, analysts would probably model centanafadine as a mid-size asset rather than a blockbuster stimulant-killer. Generic Adderall and Ritalin are cheap and deeply entrenched. Centanafadine's real opportunity is with the patients those drugs don't serve well: people who can't tolerate stimulant side effects, those with substance-use histories, patients with comorbid anxiety, and anyone who'd prefer to skip the controlled-substance hassle.

What Happens Next

The silence from both Otsuka and the FDA after the July 24 PDUFA date is notable but not unprecedented. Sometimes decisions take a few extra days to formalize and announce. The possibilities are straightforward: full approval across all age groups (best case), a narrower initial label covering only adults or adolescents (moderate case), a Complete Response Letter requesting more data (worst case), or the increasingly common scenario where the FDA and company negotiate label language behind closed doors before going public.

For the roughly 22 million Americans currently diagnosed with ADHD, the stakes are simple. They've been choosing between powerful-but-sometimes-problematic stimulants and gentler-but-weaker non-stimulants for years. Centanafadine promises something in between: a non-stimulant that actually hits the dopamine system, wraps in serotonin for good measure, and showed up with trial results strong enough to earn the FDA's expedited attention.

Now we wait for the verdict.

Genentech's $490 Million Shopping Spree Has a Dark Side

Genentech cut 103 research scientists the same week it signed a $490 million breast cancer deal with Astex Pharmaceuticals. It's the starkest example yet of big pharma's new playbook: shrink internally, shop externally.